Browse studies

Find your next paid study

27,293 recruiting studies available now

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients wi…

Urothelial CancerUrinary Bladder Neoplasms

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07566156

Phase 2

A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)

The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (S…

Liver FibrosisHepatic Cirrhosis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AstraZenecaNCT07610837

Observational

Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)

To learn about how patients view a doctor's compassion, communication skills, and professionalism based on whether the doctor uses the Electronic Health Record…

Communication SkillsProfessionalismRandomized Controlled Trial+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT07089953

Phase 3

The Revitalize Trial: Reducing Vaginal Atrophy With Fractional CO2 Laser for Breast Cancer Survivors

This phase III trial compares the effect of vaginal fractional CO2 laser therapy to placebo for the treatment of vaginal dryness in breast cancer survivors wit…

Vaginal AtrophyBreast Carcinoma

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Alliance for Clinical Trials in OncologyNCT05379153

Phase 3

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC…

ER-Positive HER2-Negative Breast Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AstraZenecaNCT07647328

Phase 4

Varenicline for Smoking Cessation in Pancreatitis: An Open-Label Trial

This study will look at how safe and how effective varenicline, a commonly used medication for smoking cessation, is in helping patients with pancreatitis stop…

PancreatitisChronic PancreatitisAcute Pancreatitis (AP)+1 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Mayo ClinicNCT07874841

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

Non Small Cell Lung CancerSmall Cell Lung CarcinomaNUT Carcinoma

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT05265429

Phase 1

A Phase 1/2, Open-label, Dose-escalation, Dose-optimization and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101/GI-101A as a Single Agent and in Combination With Pembrolizumab or Lenvatinib in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combina…

Advanced Solid TumorMetastatic Solid TumorCervical Cancer+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

GI Innovation, Inc.NCT04977453

Phase 4

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial

The primary aim is to determine whether nebulized Formoterol twice daily plus Revefenacin once daily is non-inferior to standard-of-care nebulized Albuterol an…

COPD Exacerbation

Estimated

~$25 – $1,000

Actual pay is set by the research site.

University of Tennessee Graduate School of MedicineNCT07721922

Phase 3

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC i…

Bladder Cancer

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT07419295

Phase 3

A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout

The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus peglotica…

Uncontrolled Gout

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AmgenNCT07388498

Phase 2

A Phase 2 Study of Toripalimab in Combination With Cisplatin and Docetaxel (PDT) for Induction Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for …

Squamous Cell CarcinomaHead and Neck Cancer Squamous Cell CarcinomaHead and Neck Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Massachusetts General HospitalNCT07214987